Pharma BD Deal Intelligence
Roche's $1.8B acquisition of GenMark Diagnostics moved the Swiss diagnostics giant deeper into multiplex molecular testing, though as a non-pharma diagnostics play it sits outside Roche's core drug pipeline and delivered middling returns rather than a franchise-defining win.
Roche acquired GenMark Diagnostics for $1.8B for multiplex molecular diagnostics.
Roche agrees to buy GenMark Diagnostics in $1.8 billion deal to expand molecular diagnostics.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Roche acquired GenMark Diagnostics for $1.8B for multiplex molecular diagnostics.
Roche completed $1.8B acquisition of GenMark Diagnostics, gaining ePlex multiplex molecular diagnostics platform for rapid syndromic testing.
GenMark's ePlex integrated into Roche diagnostics, complementing cobas with syndromic panel testing for respiratory, bloodstream, and GI infections.
Expanded Roche diagnostics with syndromic testing capabilities. ePlex provides differentiated rapid testing complementing existing molecular portfolio.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / GenMark Diagnostics (this deal) | 2021 | $1.8B | 61 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2021 deals · Roche Holding AG deals